Management of XXXX .

@entity1 @entity3753 @entity6583 @entity410 @entity3993 @entity198 @entity510 @entity4 @entity16 @entity2967 @entity281 @entity302 @entity67 @entity2039
@entity6583 is a common cause of @entity16 in developing countries and a major cause of @entity302 worldwide. A unique characteristic of @entity1 @entity6583 is that the living parasite is very well tolerated in @entity1 brain, so symptoms and clinical disease primarily result from death of the organism and accompanying inflammatory reaction in the @entity1 CNS. Among the diverse clinical manifestations of @entity1 @entity6583 , @entity410 are the most common, but other clinical problems occur, depending upon the localisation and viability of the parasite. Although both @entity2039 and @entity3753 are effective agents, there is controversy about their role in several forms of the disease. Systematic reviews have pointed out the limited quality of available data on therapy. At a recent international conference convened to develop guidelines for treatment of this disease, areas of consensus and disagreement on the role of antiparasitic therapy were discussed. It was clear to all that @entity3993 cannot be regarded as a single disorder; treatment needs to be modified based on the location and number of cysticerci and the host response. There was a strong consensus that there is no role for antiparasitic drugs in @entity1 with only calcified lesions. Studies suggest that @entity1 with single enhancing lesions will do well regardless of antiparasitic therapy. Antiparasitic drugs are contraindicated in @entity1 with @entity4 ( @entity198 ). Most experts strongly recommend antiparasitic therapy in @entity1 with multiple @entity510 or @entity2967 . In @entity1 with @entity67 , endoscopic removal is the preferred therapy. However, recent evidence suggests that placement of a ventricular shunt followed by antiparasitic therapy is an acceptable alternative. Standard treatment for localization-related @entity302 is effective for @entity410 caused by @entity3993 . In general, @entity410 are easily controlled in this illness. While many controversies regarding the treatment of @entity1 with @entity6583 were not resolved at the international consensus conference, @entity1 did conclude that controlled prospective studies are required to define optimal therapy for the @entity281 and that treatment of infected individuals must be individualised.
